Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) — Market Cap & Net Worth
Market Cap & Net Worth: Cyclacel Pharmaceuticals Inc (CYCC)
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) has a market capitalization of $14.25 Million ($14.25 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26168 globally and #5409 in its home market, demonstrating a -17.18% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cyclacel Pharmaceuticals Inc's stock price $6.37 by its total outstanding shares 2238980 (2.24 Million). Review how much debt does Cyclacel Pharmaceuticals Inc carry to assess the company's total debt and financial obligations.
Cyclacel Pharmaceuticals Inc Market Cap History: 2015 to 2025
Cyclacel Pharmaceuticals Inc's market capitalization history from 2015 to 2025. Data shows change from $4.03 Billion to $14.25 Million (-44.92% CAGR).
Index Memberships
Cyclacel Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #744 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2436 of 3165 |
Weight: Cyclacel Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cyclacel Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cyclacel Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
19.58x
Cyclacel Pharmaceuticals Inc's market cap is 19.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $4.03 Billion | $1.94 Million | -$14.34 Million | 2072.93x | N/A |
| 2016 | $3.55 Billion | $843.00K | -$11.79 Million | 4215.02x | N/A |
| 2018 | $406.37 Million | $150.00K | -$7.29 Million | 2709.17x | N/A |
| 2020 | $262.30 Million | $5.88K | -$8.45 Million | 44631.02x | N/A |
| 2022 | $22.40 Million | $373.00K | -$21.20 Million | 60.06x | N/A |
| 2023 | $5.98 Million | $420.00K | -$22.55 Million | 14.23x | N/A |
| 2024 | $841.86K | $43.00K | -$11.21 Million | 19.58x | N/A |
Competitor Companies of CYCC by Market Capitalization
Companies near Cyclacel Pharmaceuticals Inc in the global market cap rankings as of June 18, 2026.
Key companies related to Cyclacel Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Cyclacel Pharmaceuticals Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Cyclacel Pharmaceuticals Inc's market cap moved from $4.03 Billion to $ 14.25 Million, with a yearly change of -44.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $14.25 Million | +1592.82% |
| 2024 | $841.86K | -85.92% |
| 2023 | $5.98 Million | -73.31% |
| 2022 | $22.40 Million | -82.85% |
| 2021 | $130.64 Million | -50.19% |
| 2020 | $262.30 Million | -41.72% |
| 2019 | $450.03 Million | +10.74% |
| 2018 | $406.37 Million | -65.23% |
| 2017 | $1.17 Billion | -67.11% |
| 2016 | $3.55 Billion | -11.82% |
| 2015 | $4.03 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Cyclacel Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.25 Million USD |
| MoneyControl | $14.25 Million USD |
| MarketWatch | $14.25 Million USD |
| marketcap.company | $14.25 Million USD |
| Reuters | $14.25 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cyclacel Pharmaceuticals Inc
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala… Read more